Cancer caregivers in emerging and young adulthood (ages 18-35) are an underresearched and unsupported group of caregivers, and yet they are not uncommon. To address this critical support gap, the goal of this study is to develop and pilot test a caregiving support intervention specifically tailored for emerging and young adults caring for a parent with cancer. This phase of the study is intended to capture feedback on the intervention via focus groups with emerging and young adult caregivers of a parent with cancer.

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

This is a Phase 3 study. Phase 3 studies can involve testing a study drug in hundreds to thousands of people over several years. The main purpose of this study is to see if the study drug, Niraparib, works better than the comparator drug in people who have just been diagnosed with glioblastoma. The comparator drug is a type of chemotherapy commonly used to treat newly diagnosed glioblastoma.
This study includes:
• Phase 1, where subjects will take either the study drug or comparator drug. All participants will also receive radiotherapy in this phase. In this phase, there will be about 45 visits to the study center. The duration for this phase will last as long as the cancer does not get worse.
• Phase 2, where subjects will continue with the same drug given in Phase 1 without radiotherapy. In this phase there will be about 53 visits to the study center and participation in the study will last for 42 weeks.
There are four periods of the study, the screening period (last about 1 month), study treatment period (as long as desired or up to 8 months), safety follow-up period (1 month), and long-term follow up period (up to 5 years).
Some procedures in this study are blood tests, memory, speech and thinking test, ECG, tissue sample, bone marrow biopsy, and imaging test. Some risks include the cancer could get worse and there are risks associated with the study drugs (for example, low appetite, difficulty speaking, headaches, vomiting, nausea, diarrhea, etc.)

This study is for adult patients with head and neck cancer who are at risk of recurrence. The purpose of this study is to evaluate whether the use of Indocyanine Green (ICG) dye allows for better identification of tumor tissue during surgical procedures. Participation will include standard of care visits along with administration of ICG dye and imaging during surgery. Participation in this study will last approximately 6 weeks.

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

The aim of this supplement study is to learn more about the emotional health and symptom needs of long-term cancer survivors (over 5 years since diagnosis) living with likely incurable disease. Participants in this qualitative substudy will be individuals who are long-term cancer survivors who participated in another study of depression in individuals with likely incurable cancer. We will recruit long-term cancer survivors with likely incurable cancer to participate in one-time, 45- to 60-minute in-depth, semi-structured interviews. We will ask patients about emotional health and symptom burden concerns and elicit attitudes toward digital mental health interventions (DMHI) and preferences for intervention type and delivery. Findings will inform the development of digital mental health interventions tailored to this patient population.

The aim of this supplement study is to learn more about the emotional health and symptom needs of long-term cancer survivors (over 5 years since diagnosis) living with likely incurable disease. Participants in this qualitative substudy will be individuals who are long-term cancer survivors who participated in another study of depression in individuals with likely incurable cancer. We will recruit long-term cancer survivors with likely incurable cancer to participate in one-time, 45- to 60-minute in-depth, semi-structured interviews. We will ask patients about emotional health and symptom burden concerns and elicit attitudes toward digital mental health interventions (DMHI) and preferences for intervention type and delivery. Findings will inform the development of digital mental health interventions tailored to this patient population.

The aim of this supplement study is to learn more about the emotional health and symptom needs of long-term cancer survivors (over 5 years since diagnosis) living with likely incurable disease. Participants in this qualitative substudy will be individuals who are long-term cancer survivors who participated in another study of depression in individuals with likely incurable cancer. We will recruit long-term cancer survivors with likely incurable cancer to participate in one-time, 45- to 60-minute in-depth, semi-structured interviews. We will ask patients about emotional health and symptom burden concerns and elicit attitudes toward digital mental health interventions (DMHI) and preferences for intervention type and delivery. Findings will inform the development of digital mental health interventions tailored to this patient population.

The aim of this supplement study is to learn more about the emotional health and symptom needs of long-term cancer survivors (over 5 years since diagnosis) living with likely incurable disease. Participants in this qualitative substudy will be individuals who are long-term cancer survivors who participated in another study of depression in individuals with likely incurable cancer. We will recruit long-term cancer survivors with likely incurable cancer to participate in one-time, 45- to 60-minute in-depth, semi-structured interviews. We will ask patients about emotional health and symptom burden concerns and elicit attitudes toward digital mental health interventions (DMHI) and preferences for intervention type and delivery. Findings will inform the development of digital mental health interventions tailored to this patient population.

The aim of this supplement study is to learn more about the emotional health and symptom needs of long-term cancer survivors (over 5 years since diagnosis) living with likely incurable disease. Participants in this qualitative substudy will be individuals who are long-term cancer survivors who participated in another study of depression in individuals with likely incurable cancer. We will recruit long-term cancer survivors with likely incurable cancer to participate in one-time, 45- to 60-minute in-depth, semi-structured interviews. We will ask patients about emotional health and symptom burden concerns and elicit attitudes toward digital mental health interventions (DMHI) and preferences for intervention type and delivery. Findings will inform the development of digital mental health interventions tailored to this patient population.